The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...

On Monday, Eli Lilly And Co (NYSE:LLY) inked two strategic collaborations ... to research and develop cancer treatments. Under this new agreement, the parties will leverage AdvanCell's proprietary ...

We came across a bullish thesis on Eli Lilly and Company (LLY ... which is set to expand into new therapeutic areas. Despite increasing competition, the company remains strong in both the U.S ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

In Q4 2024, Eli Lilly’s top-performing drugs included Mounjaro, which saw a 60% increase in revenue, and Zepbound, which is set to expand into new therapeutic areas. Despite increasing competition, ...

Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

In its fourth quarter 2024 investor letter, Alger Spectra Fund emphasized stocks such as Eli Lilly and Company (NYSE ... following inventory building in the prior quarter, which led to an 11% ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.